PathMaker Neurosystems Inc. is advancing the MyoRegulator® device through the CALM study, targeting the ALS market, which currently has approximately 30,000 patients in the U.S. and 5,000 new diagnoses annually. The study aims to establish preliminary safety and efficacy data, which could position the MyoRegulator® as a novel treatment option in a market with limited effective therapies. The device's non-invasive nature may appeal to patients and healthcare providers, potentially enhancing adoption rates. However, the competitive landscape includes established therapies like Riluzole and Edaravone, which may pose challenges in market penetration. The successful completion of this study could pave the way for a larger pivotal trial, attracting interest from investors and collaborators, particularly given the involvement of the U.S. Department of Defense as a collaborator.